Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D B Hunninghake

Showing results (21-30 of 138) with videos related to

Pageof 14
Sort By:
The American Journal of Managed Care|February 24, 2001
Introduction: missing the target with lipid-lowering therapyD B Hunninghake, J M McKenney
Postgraduate Medicine|August 1, 1970
AntihistaminesK F Tempero, D B Hunninghake
Artery|January 1, 1985
Effect of time of administration of cholestyramine on plasma lipids and lipoproteinsJ R Peters, D B Hunninghake
Clinical Pharmacology and Therapeutics|March 1, 1986
Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazideD B Hunninghake, D M Hibbard
Archives of Internal Medicine|July 25, 1994
Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physicianJ L Probstfield, D B Hunninghake
Journal of Clinical Pharmacology|February 1, 1981
Inhibition of histamine-stimulated increases in heart rate in man with the H2-histamine receptor antagonist cimetidineV R Grund, D B Hunninghake
The American Journal of Medicine|November 27, 1987
Effect of fibric acid derivatives on blood lipid and lipoprotein levelsD B Hunninghake, J R Peters
Metabolism: Clinical and Experimental|June 1, 1981
Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemiaD B Hunninghake, C Bell, L Olson
Atherosclerosis|November 1, 1980
Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemiaD B Hunninghake, C Bell, L Olson
Atherosclerosis|December 23, 1998
Effect of human apolipoprotein E isoforms on plasma lipids, lipoproteins and apolipoproteins in apolipoprotein E-deficient miceG Wu, J Yuan, D B Hunninghake
Pageof 14

Showing results (21-30 of 138) with videos related to

Sort By:
Pageof 14
The American Journal of Managed Care|February 24, 2001
Introduction: missing the target with lipid-lowering therapyD B Hunninghake, J M McKenney
Postgraduate Medicine|August 1, 1970
AntihistaminesK F Tempero, D B Hunninghake
Artery|January 1, 1985
Effect of time of administration of cholestyramine on plasma lipids and lipoproteinsJ R Peters, D B Hunninghake
Clinical Pharmacology and Therapeutics|March 1, 1986
Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazideD B Hunninghake, D M Hibbard
Archives of Internal Medicine|July 25, 1994
Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physicianJ L Probstfield, D B Hunninghake
Journal of Clinical Pharmacology|February 1, 1981
Inhibition of histamine-stimulated increases in heart rate in man with the H2-histamine receptor antagonist cimetidineV R Grund, D B Hunninghake
The American Journal of Medicine|November 27, 1987
Effect of fibric acid derivatives on blood lipid and lipoprotein levelsD B Hunninghake, J R Peters
Metabolism: Clinical and Experimental|June 1, 1981
Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemiaD B Hunninghake, C Bell, L Olson
Atherosclerosis|November 1, 1980
Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemiaD B Hunninghake, C Bell, L Olson
Atherosclerosis|December 23, 1998
Effect of human apolipoprotein E isoforms on plasma lipids, lipoproteins and apolipoproteins in apolipoprotein E-deficient miceG Wu, J Yuan, D B Hunninghake
Pageof 14